RTSN.US Retension Pharmaceuticals, Inc. Common Stock
- Market cap
- USD 95.5M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RTSN.US undervalued?
Graham numberThe Graham number of Retension Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Retension Pharmaceuticals, Inc. Common Stock fundamental analysis
No fundamental analysis for Retension Pharmaceuticals, Inc. Common Stock yet.
Retension Pharmaceuticals, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Retension Pharmaceuticals, Inc. Common Stock
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascula…
Full company profileRetension Pharmaceuticals, Inc. Common Stock financial statements
Retension Pharmaceuticals, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -2.28M | -6.88M |
| EBITDA | -2.28M | -6.88M |
| Net Income | -1.91M | -6.30M |
| EPS | -0.23 | -0.76 |
| Balance Sheet | ||
| Total Assets | 8.37M | 21.4M |
| Total Liabilities | 10.1M | 29.2M |
| Shareholders' Equity | -1.73M | -7.78M |
| Cash & Short-term Investments | 8.19M | 18.9M |
| Cash Flow | ||
| Operating Cash Flow | -1.76M | -7.78M |
| Capital Expenditure | 0.00 | 0.00 |
| Free Cash Flow | -1.76M | -7.78M |
| Ratios | ||
| ROA | -22.8% | -29.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Retension Pharmaceuticals, Inc. Common Stock dividends
Retension Pharmaceuticals, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Retension Pharmaceuticals, Inc. Common Stock
- Insiders 25.70%
- Institutions 23.34%
- Public & others 50.96%
- Shares outstanding 8.33M
- Free float 536K
Retension Pharmaceuticals, Inc. Common Stock company profile
- Company name
- Retension Pharmaceuticals, Inc. Common Stock
- Ticker
- RTSN.US
- Exchange
- USA Stocks
- Listed since
- Oct 9, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- 1104 West Broad Street #1029, Falls Church, VA, United States, 22046
- Phone
- (703) 940-9761
- Website
- retensionpharmaceuticals.com
About Retension Pharmaceuticals, Inc. Common Stock
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
Retension Pharmaceuticals, Inc. Common Stock management
10- Dr. Michael Joseph Berendt Ph.D.Executive Chairman · born 1949
- Mr. Eric Keller J.D.Co-founder, CEO & Director · born 1965
- Dr. Paul Sweetnam Ph.D.Co-Founder, Chief Scientific Officer & Secretary · born 1956
- Mr. Alexander Duke Schwartz M.B.A.Chief Financial Officer · born 1986
- Ms. Sabine Bisson Ph.D.Chief Operations Officer · born 1971
- Mr. Robert C. WongVP, Chief Accounting Officer & Principal Accounting Officer · born 1966
- Mr. Craig Michael Audet Ph.D.Chief Regulatory & Compliance Officer · born 1964
- Dr. Alison D. Schecter FACC, M.D.Chief Medical Officer · born 1964
- Dr. Bridget McCarthy Cole Ph.D.Head of CMC
- Ms. LeAnne Bloedon M.S.Executive Vice President of Clinical Development & Operations